Compared with PPD, ginsenoside Rg3, and ginsenoside Rh2, ginsenoside PPT is more powerful for inhibiting the viability and invasiveness of lung cancer cell, especially lung squamous cell, according to a study published on the American Journal of Translational Research.
The study titled “The antitumor activity study of ginsenosides and metabolites in lung cancer cell” was conducted by researchers at Jiangxi Normal University and Fudan University Shanghai Medical College with the research task to evaluate the antitumor activity of PPD, PPT, ginsenoside Rg3 and ginsenoside Rh2 in lung cancer cell.
As in vitro experiments showed, the viability of the lung squamous cell line SK-MES-1 treated with ginsenoside PPT was decreased to 66.8%, and this effect equaled to Cisplatin. Besides, ginsenoside Rg3 was discovered to have the highest stimulatory effect on apoptosis, and ginsenoside PPT showed the highest inhibitory effect on cell invasiveness in the lung adenocarcinoma cell line A549 and the lung squamous cell line SK-MES-1.
“These results indicated that both ginsenosides and two metabolites have antitumor activity on lung cancer cell in vitro. However, ginsenoside PPT is more powerful for inhibiting the viability and invasiveness of lung cancer cell, especially lung squamous cell. Ginsenoside Rg3 has the best pro-apoptosis effects,” said authors in a statement.
The research suggested that ginsenoside PPT is a potential extract for addressing lung cancer.
